Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
roseburia hominis
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Roseburia hominis is a flagellated, Gram-positive, obligate anaerobic bacterium belonging to the Lachnospiraceae family within the Firmicutes phylum. It is a commensal organism that inhabits the human colon and is recognized for its ability to produce short-chain fatty acids (SCFAs), particularly butyrate. Butyrate serves as an essential energy source for colonocytes, supports gut barrier function, modulates immune responses (notably by expanding regulatory T cells), and helps maintain intestinal homeostasis. Decreased levels of R. hominis have been observed in patients with ulcerative colitis and obesity, suggesting its role in maintaining gut health and metabolic balance. Experimental studies indicate that R. hominis can protect against colitis in animal models by enhancing gut barrier integrity and promoting anti-inflammatory immune pathways—potentially via TLR5-flagellin signaling[1][2][3][4][7].
- Other names
- Roseburia hominis
02
Targets
TLR5
Beyond the preview
Go deeper on roseburia hominis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on roseburia hominis.